885 West Georgia Street
About Sierra Oncology
Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. We are an ambitious company, oriented towards achieving the successful registration and commercialization of our drug candidates and we have a world-class management team with a proven track record of success in oncology drug development.
CEO: Nick Glover
CBO: Angie You
CMO: Mark Kowalski
CFO: Sukhi Jagpal
Please click here for Sierra Oncology job opportunities.
Please click here for clinical trial information.
90 articles with Sierra Oncology
Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action
Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models
Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019
Sierra Oncology, Inc. reported its financial and operational results for the year ended December 31, 2018.
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models
"Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC)
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it will host an Analyst & Investor call on Monday, December 3rd
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium
SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN‑overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models
Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models.
Momelotinib regulatory pathway clarity anticipated in H1 2019
"Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients
Sierra Oncology (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today reported that clinical data from a translational biology study of momelotinib in 41 transfusion dependent patients with myelofibrosis (MF) will be reported in a poster at ASH 2018.
Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"
Sierra Oncology, Inc. today announced that it will host a Key Opinion Leader call on the topic of "Unmet Medical Needs in Myelofibrosis" on Wednesday, October 17 at 10:30 am Eastern Time.
Up to $15 million available in three $5 million tranches; additional $25 million potentially available
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019
Presentation scheduled for 9:10 a.m. ET on August 15, 2018